Healthcare's Valuation Disconnect Signals Opportunity for Asia's Wealth Allocators
The healthcare sector is currently trading at a significant discount to the broader market, presenting a compelling opportunity for wealth allocators in Asia. This article delves into the key factors driving this opportunity and the potential benefits for investors.
A Sector Out of Favor, But Not Out of Form
Healthcare's underperformance over the past two years has been a result of political uncertainty in the United States, rising interest rates, and the shift of capital towards AI and technology stocks. However, beneath the surface, the sector's fundamentals remain strong. The resolution of the most-favored-nation pricing dispute with the US government has removed a major political headwind, and small and mid-cap biotech companies are performing well due to strong clinical results and acquisition activity from large pharma.
Healthcare providers, particularly US health insurance companies, have also shown signs of improvement in the first quarter of 2026, with medical costs being absorbed by high premiums. However, medtech remains under pressure due to uncertainty around the US government's decision not to extend Affordable Care Act subsidies.
The Valuation Case
The valuation disconnect in healthcare is even more pronounced when compared to the S&P 500. The MSCI World Healthcare Index trades at around 17 times next-12-month earnings, compared to approximately 21 times for the S&P 500. This represents a significant discount, with the price-to-earnings (P/E) ratio standing at 0.82 times the broader market, well below the 10-year average.
This undervaluation presents a compelling entry point for investors, especially as the capital currently concentrated in technology and AI needs to be allocated elsewhere. The healthcare sector's defensive qualities and innovation-driven growth make it an attractive complement to concentrated technology positions.
Innovation as the Growth Engine
Innovation is a key driver of long-term growth in healthcare. New products and treatment modalities are creating entirely new revenue pools. For example, lipoprotein(a) (Lp(a)) represents a multi-billion-dollar market opportunity, with no approved therapy currently available. Several companies are in late-stage trials, with data expected in 2026.
In medtech, robotic surgery is advancing with the introduction of AI-driven features, such as simulated surgical training and tissue pressure sensing. The continuous glucose monitoring market is projected to grow significantly, and soft-tissue surgical robotics is expected to double in value over the next few years.
AI as Enabler, Not Disruptor
AI is playing a crucial role in healthcare, primarily as an efficiency tool rather than a disruptor. In pharma and biotech, AI is being used to accelerate drug development, improve patient selection, and predict toxicity profiles, potentially saving billions in costs. For health insurance companies, AI enables automation of invoice processing and contract management.
The regulatory environment in healthcare provides natural barriers to software disruption, as hardware-based businesses have a head start in developing their software further.
M&A as a Structural Imperative
Patent expirations pose a significant risk to big pharma, with hundreds of billions of dollars in revenue at stake. M&A is an imperative rather than an option, as companies need to replenish depleted pipelines and maintain their market position. The 20 largest biopharma companies hold over $1 trillion in combined cash and debt capacity, enabling major transactions.
Building the Case for Allocation
Healthcare remains structurally underweight in most portfolios, but its defensive qualities and innovation-driven growth make it an increasingly logical complement to concentrated technology positions. Wealth managers and family office professionals are recognizing the opportunity, as evidenced by the recent roundtable discussion.
Bellevue Asset Management, a specialist healthcare investor, positions itself as a partner for investors seeking differentiated healthcare exposure. With a focus on publicly listed healthcare equities and a team of investment professionals with diverse backgrounds, Bellevue is well-positioned to capitalize on the current dislocation in the sector.
